Topline data from the open-label, Phase 1b clinical trial

Diffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million, due to demand

announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 29,268,294 shares of common stock of the Company at a price to the public of $1.025 per share, less underwriting discounts and commissions.

finance.yahoo.com/news/diffusion-pharmaceuticals-increases-previously-announced-030200522.html

Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients

No Dose Limiting Toxicities or Serious Adverse Events Observed in Dosing Regimen Previously Untested in Clinical Trial Setting.

completion and topline data from the open-label, Phase 1b clinical trial of its novel.

finance.yahoo.com/news/diffusion-pharmaceuticals-completes-phase-1b-123500412.html